<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03679182</url>
  </required_header>
  <id_info>
    <org_study_id>HE591547</org_study_id>
    <nct_id>NCT03679182</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care</brief_title>
  <official_title>A Pilot Study on Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral olanzapine showed superior antiemetic efficacy to metoclopramide as rescue treatment to&#xD;
      control breakthrough emesis induced by chemotherapy. This study aims to evaluate safety and&#xD;
      efficacy of olanzapine for nausea and vomiting in advanced cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a pilot study; open-label prospective clinical trial. Oral olanzapine 5 mg&#xD;
      tablet will be given to patients who fail two standard treatment medications for nausea and&#xD;
      vomiting within 30 minutes after the first vomiting episode. Other doses of olanzapine will&#xD;
      be given at 12, 24, and 36 hours following the first dose concurrently with standard regimen.&#xD;
&#xD;
      Patients with emesis will be followed up after receiving olanzapine every 12 hour for 48&#xD;
      hours. We will record the frequency of vomiting, nausea, and retching.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emesis control</measure>
    <time_frame>48 hours</time_frame>
    <description>Percentage of patients without emesis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>End Stage Cancer</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine 5 mg at 0, 12, 24 and 36 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>olanzapine 5 mg Tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years.&#xD;
&#xD;
          2. Diagnosis of advanced malignancy.&#xD;
&#xD;
          3. Failed two standard medications for nausea/vomiting (after 6 hours from last dose).&#xD;
&#xD;
          4. Adequate organ function, including the following:&#xD;
&#xD;
               1. Hepatic: bilirubin ≤1.5 times the upper limit of normal (x ULN); aspartate&#xD;
                  aminotransferase (AST), and alanine aminotransferase (ALT) ≤3.0 x ULN (AST, and&#xD;
                  ALT ≤5 x ULN is acceptable if liver has tumor involvement), alkaline phosphatase&#xD;
                  (AP) ≤5.0 x ULN.&#xD;
&#xD;
               2. Renal: calculated creatinine clearance (CrCl) ≥30 mL/min based on the original&#xD;
                  weight based Cockcroft and Gault formula.&#xD;
&#xD;
          5. Expected life expectancy &gt; 1 month.&#xD;
&#xD;
          6. Patients must be able to read Thai.&#xD;
&#xD;
          7. Patients must sign an informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with history of abdominal radiotherapy.&#xD;
&#xD;
          2. Patients who receive chemotherapy within 1 week.&#xD;
&#xD;
          3. Patients who take fluoxetine.&#xD;
&#xD;
          4. Patients with heart failure or myocardial infarction in the past 6 months.&#xD;
&#xD;
          5. Patients with QTc prolongation from baseline ECG.&#xD;
&#xD;
          6. Known hypersensitivity to olanzapine.&#xD;
&#xD;
          7. Patients who are unwilling to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Attakorn Raksasataya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarin Chindaprasirt, MD</last_name>
    <phone>+66846831097</phone>
    <email>jarich@kku.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jarin Chindaprasirt</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaruda Sringam, Master</last_name>
      <phone>6643366592</phone>
      <email>talnurse8@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jarin Chindaprasirt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Attakorn Raksasataya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suthan Chanthawong, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Jarin Chindaprasirt</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

